Sebetralstat (Ekterly) for Treatment of Hereditary Angioedema Attacks
Abstract
Sebetralstat (Ekterly – Kalvista), an oral plasma kallikrein inhibitor, has been approved by the FDA for treatment of acute hereditary angioedema (HAE) attacks in patients ≥12 years old. It is the first oral drug to be approved in the US for this indication. The intravenous C1 esterase inhibitors (C1INHs) Berinert and Ruconest, the subcutaneous plasma kallikrein inhibitor ecallantide (Kalbitor), and the subcutaneous bradykinin B2 receptor antagonist icatibant (Firazyr) have been available for years for on-demand treatment of HAE attacks; all of these drugs except ecallantide can be self-administered, but treatment delays are common.
Fields of Study & Subjects
Coagulation
Bradykinin
Polyphosphates
and Angioedema
Complement system in diseases
Hemophilia Treatment and Research
Publication details
- Journal / source
- The medical letter on drugs and therapeutics/The medical letter
- Volume
- 68
- Issue
- 1748
- Pages
- 29–30
- Publication date
- 6 February 2026
- Language
- EN